These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Whole body MR imaging in neurofibromatosis type 1. Van Meerbeeck SF; Verstraete KL; Janssens S; Mortier G Eur J Radiol; 2009 Feb; 69(2):236-42. PubMed ID: 19091504 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Mautner VF; Brenner W; Fünsterer C; Hagel C; Gawad K; Friedrich RE Anticancer Res; 2007; 27(4A):1819-22. PubMed ID: 17649778 [TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700 [TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1. Friedrich RE; Keiner D; Hagel C Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027 [TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022 [TBL] [Abstract][Full Text] [Related]
15. Neurological complications involving the central nervous system in neurofibromatosis type 1. Hsieh HY; Wu T; Wang CJ; Chin SC; Chen YR Acta Neurol Taiwan; 2007 Jun; 16(2):68-73. PubMed ID: 17685129 [TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545 [TBL] [Abstract][Full Text] [Related]
18. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma. Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292 [TBL] [Abstract][Full Text] [Related]
19. [Pathologic characteristics of the most frequent peripheral nerve tumors]. Coulon A; Milin S; Laban E; Debiais C; Jamet C; Goujon JM Neurochirurgie; 2009 Oct; 55(4-5):454-8. PubMed ID: 19744677 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of plexiform neurofibroma in neurofibromatosis type 1 in 18 family members of 3 generations: ultrasonography and magnetic resonance imaging a diagnostic supplement. Sehgal VN; Sharma S; Oberai R Int J Dermatol; 2009 Mar; 48(3):275-9. PubMed ID: 19261016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]